Chondroprotective agents: Glucosamine and chondroitin

Foot and Ankle Clinics

Volumn 8, Issue 2, 2003, Pages 201-219

  Hungerford, Marc W ^a   Valaik, Daniel ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHONDROITIN SULFATE; GLUCOSAMINE; NONSTEROID ANTIINFLAMMATORY AGENT; CHONDROITIN;

ANTICOAGULATION; ANTIINFLAMMATORY ACTIVITY; BIOSYNTHESIS; CARTILAGE; CHONDROPROTECTION; DISEASE COURSE; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG MARKETING; DRUG SAFETY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; OSTEOARTHRITIS; REVIEW; SUPPLEMENTATION; BIOAVAILABILITY; DRUG COMBINATION; HISTOLOGY; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY;

BIOLOGICAL AVAILABILITY; CARTILAGE; CHONDROITIN; DRUG THERAPY, COMBINATION; GLUCOSAMINE; HUMANS; OSTEOARTHRITIS;

EID: 0141543836     PISSN: 10837515     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1083-7515(03)00043-3     Document Type: Review

References (109)

1. Felson D.T. Epidemiology of hip and knee osteoarthritis. Epidemiol Rev. 10:1988;1-28
2. Lane N.E., Thompson J.M. Management of osteoarthritis in the primary-care setting: an evidence-based approach to treatment. Am J Med. 103:(6A):1997;25S-30S
3. Creamer P., Hochberg M.C. Osteoarthritis. Lancet. 350:(9076):1997;503-508
4. Theodosakis J., Adderly B., Fox B. The arthritis cure. 1997;St. Martins Press, New York
5. Sandy J.D., Plaas A.H. Age-related changes in the kinetics of release of proteoglycans from normal rabbit cartilage explants. J Orthop Res. 4:(3):1986;263-272
6. Ilic M.Z., Haynes S.R., Winter G.M., et al. Kinetics of release of aggrecan from explant cultures of bovine cartilage from different sources and from animals of different ages. Acta Orthop Scand Suppl. 266:1995;33-37
7. Brandt K., Radin E. The ohysiology of articular stress: osteoarthritis. Hosp Pract. 1:1987;103-126
8. Martin D.F. Pathomechanics of knee osteoarthritis. Med Sci Sports Exerc. 26:(12):1994;1429-1434
9. Rosenberg A.E. Joints. Cotran R.S., Kumar V., Robbins S. Pathologic basis of disease. 1994;1243-1248 WB Saunders, Philadelphia
10. Wheater P., Burkett H.G., Stevens A., et al. Basic histopathology. 1991;Churchill Livingston, New York
11. Bradley J.D., Brandt K.D., Katz B.P., et al. Comparison of an antiinflammatory dose of ibuprofen, an analgesic dose of ibuprofen, and acetaminophen in the treatment of patients with osteoarthritis of the knee [see comments]. N Engl J Med. 325:(2):1991;87-91
12. Williams H.J., Ward J.R., Egger M.J., et al. Comparison of naproxen and acetaminophen in a two-year study of treatment of osteoarthritis of the knee [comments]. Arthritis Rheum. 36:(9):1993;1196-1206
13. Brandt K.D. Effects of nonsteroidal anti-inflammatory drugs on chondrocyte metabolism in vitro and in vivo. Am J Med. 83:(5A):1987;29-34
14. Brandt K.D. The mechanism of action of nonsteroidal antiinflammatory drugs. J Rheumatol Suppl. 27:1991;120-121
15. Brandt K.D., Palmoski M.J. Effects of salicylates and other nonsteroidal anti-inflammatory drugs on articular cartilage. Am J Med. 77:(1A):1984;65-69
16. Palmoski M.J., Brandt K.D. Aspirin aggravates the degeneration of canine joint cartilage caused by immobilization. Arthritis Rheum. 25:(11):1982;1333- 1342
17. Palmoski M.J., Brandt K.D. Effect of salicylate on proteoglycan metabolism in normal canine articular cartilage in vitro. Arthritis Rheum. 22:(7):1979;746-754
18. Palmoski M.J., Brandt K.D. Effects of some nonsteroidal antiinflammatory drugs on proteoglycan metabolism and organization in canine articular cartilage. Arthritis Rheum. 23:(9):1980;1010-1020
19. Palmoski M.J., Colyer R.A., Brandt K.D. Marked suppression by salicylate of the augmented proteoglycan synthesis in osteoarthritic cartilage. Arthritis Rheum. 23:(1):1980;83-91
20. Ghosh P. Anti-rheumatic drugs and cartilage. Baillieres Clin Rheumatol. 2:(2):1988;309-338
21. Lentini A., Ternai B., Ghosh P. Synthetic inhibitors of human granulocyte elastase, Part 4. Inhibition of human granulocyte elastase and cathepsin G by non-steroidal anti-inflammatory drugs (NSAID)s. Biochem Int. 15:(6):1987;1069-1078
22. Rashad S., Revell P., Hemingway A., et al. Effect of non-steroidal anti-inflammatory drugs on the course of osteoarthritis [comments]. Lancet. 2:(8662):1989;519-522
23. Ronningen H., Langeland N. Indomethacin treatment in osteoarthritis of the hip joint. Does the treatment interfere with the natural course of the disease? Acta Orthop Scand. 50:(2):1979;169-174
24. Fries J.F., Williams C.A., Bloch D.A., et al. Nonsteroidal anti-inflammatory drug-associated gastropathy: incidence and risk factor models. Am J Med. 91:1991;213-222
25. Singh G. Recent considerations in nonsteroidal anti-inflammatory drug gastropathy. Am J Med. 105:(1B):1998;31S-38S
26. Ghosh P., Brooks P. Chondroprotection-exploring the concept [editorial]. J Rheumatol. 18:(2):1991;161-166
27. Roden L. Effect of hexosamines on the synthesis of chondroitin sulphuric acid in vitro. Ark Kemi. 10:1956;345-352
28. Vidal y Plana R.R., Bizzarri D., Rovati A.L. Articular cartilage pharmacology: I. In vitro studies on glucosamine and non steroidal antiinflammatory drugs. Pharmacol Res Commun. 10:(6):1978;557-569
29. Vidal y Plana R.R., Karzel K. [Glucosamine: its value for the metabolism of articular cartilage. 2. Studies on articular cartilage. 1. Biochemistry of proteoglycans, studies on in-vitro cultures of embryonal mouse fibroblasts and bone germs]. Glukosamin: Seine Bedeutung fur den knorpelstoff-wechsel der Gelenke. 1. Biochemie der Proteoglykane, untersuchungen an in vitro-kulturen embryonaler Mause-Fibroblasten und knochen-anlagen (German) Fortschr Med. 98:(21):1980;801-806
30. Karzel K., Domenjoz R. Effects of hexosamine derivatives and uronic acid derivatives on glycosaminoglycane metabolism of fibroblast cultures. Pharmacology. 5:(6):1971;337-345
31. 14C-markiertes glukosamin. Report of the nuclear medicine laboratory. University Clinic of Bonn. 1970
32. Jimenez S., Dodge G. The effects of glucosamine sulfate on human chondrocyte gene expression. Osteoarthritis Cartilage. 5:1997;72
33. Vidal y Plana R.R., Karzel K. [Glucosamine: its value for the metabolism of articular cartilage. 1. Biochemistry of proteoglycans, studies on in-vitro cultures of embryonal mouse fibroblasts and bone germs]. Fortschr Med. 98:(15):1980;557-562
34. Sandy J.D., Gamett D., Thompson V., et al. Chondrocyte-mediated catabolism of aggrecan: aggrecanase-dependent cleavage induced by interleukin-1 or retinoic acid can be inhibited by glucosamine. Biochem J. 335:(Pt 1):1998;59-66
35. Shikhman A.R., Kuhn K., Alaaeddine N., et al. N-acetylglucosamine prevents IL-1 beta-mediated activation of human chondrocytes. J Immunol. 166:(8):2001;5155-5560
36. Fenton J.I., Chlebek-Brown K.A., Peters T.L., et al. Glucosamine HCl reduces equine articular cartilage degradation in explant culture. Osteoarthritis Cartilage. 8:(4):2000;258-265
37. Setnikar I., Cereda R., Pacini M.A., et al. Antireactive properties of glucosamine sulfate. Arzneimittelforschung. 41:(2):1991;157-161
38. McCarty M.F. Enhanced synovial production of hyaluronic acid may explain rapid clinical response to high-dose glucosamine in osteoarthritis. Med Hypotheses. 50:(6):1998;507-510
39. Conrozier T., Mathieu P., Piperno M., et al. Glucosamine sulfate significantly reduced cartilage destruction om a rabbit model of osteoarthritis. Arthritis Rheum. 41s:1998;147
40. Hua J., Sakamoto K., Nagaoka I. Inhibitory actions of glucosamine, a therapeutic agent for osteoarthritis, on the functions of neutrophils. J Leukoc Biol. 71:(4):2002;632-640
41. Ma L., et al. Immunosuppressive effects of glucosamine. J Biol Chem. 277:(42):2002;39343-39349
42. Crolle G., D'Este E. Glucosamine sulphate for the management of arthrosis: a controlled clinical investigation. Curr Med Res Opin. 7:(2):1980;104-109
43. Bohne W. Glukosamine in der donservativen arthosebehandlung. Med Welt. 30:1969;1668-1671
44. Dustmann H.O., Puhl W. Die intraartikulaere injektionstherapie der arthrose- klinische und tierexperimentelle untersuchungen. Orthop Praxis. 14:1978;682-684
45. Eichler J., Nöh E. Behandlung der arthrosis deformans durch beeinflussung des knorpelstoffwechsels. Orthop Praxis. 6:1970;225-229
46. Mund-Hoym W.D. [The treatment of hip and knee joint arthroses]. ZFA (Stuttgart). 56:(31):1980;2153-2159
47. Lopes Vaz A. Double-blind clinical evaluation of the relative efficacy of ibuprofen and glucosamine sulphate in the management of osteoarthrosis of the knee in out-patients. Curr Med Res Opin. 8:(3):1982;145-149
48. Tapadinhas M.J., Rivera I.C., Bignamini A.A. Oral glucosamine sulphate in the management of arthrosis: report on a multi-centre open investigation in Portugal. Pharmatherapeutica. 3:(3):1982;157-168
49. Qiu G.X., Gao S.N., Giacovelli G., et al. Efficacy and safety of glucosamine sulfate versus ibuprofen in patients with knee osteoarthritis. Arzneimittelforschung. 48:(5):1998;469-474
50. Pujalte J.M., Llavore E.P., Ylescupidez F.R. Double-blind clinical evaluation of oral glucosamine sulphate in the basic treatment of osteoarthrosis. Curr Med Res Opin. 7:(2):1980;110-114
51. Drovanti A., Bignamini A.A., Rovati A.L. Therapeutic activity of oral glucosamine sulfate in osteoarthrosis: a placebo-controlled double-blind investigation. Clin Ther. 3:(4):1980;260-272
52. Hehne H.J., Blasius K., Ernst H.U. [Therapy of gonarthrosis using chondroprotective substances. Prospective comparative study of glucosamine sulphate and glycosaminoglycan polysulphate]. Die Therapie der Gonarthrose mit chondroprotektiven substanzen. Prospektive vergleichsstudie zwischen Glukosaminsulfat und Glykosamino gly-kanpolysulfat Fortschr Med. 102:(24):1984;676-682. [in German]
53. Muller Fassbender H., Bach G.L., Haase W., et al. Glucosamine sulfate compared to ibuprofen in osteoarthritis of the knee. Osteoarthritis Cartilage. 2:(1):1994;61-69
54. Noack W., Fischer M., Forster K.K., et al. Glucosamine sulfate in osteoarthritis of the knee. Osteoarthritis Cartilage. 2:(1):1994;51-59
55. Pavelka K., Gatterova J., Olejarova M., et al. Glucosamine sulfate use and delay of progression of knee osteoarthritis: a 3-year, randomized, placebo-controlled, double-blind study. Arch Intern Med. 162:(18):2002;2113-2123
56. Reginster J.Y., Deroisy R., Rovanti L.C., et al. Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet. 357:(9252):2001;251-256
57. Reichelt A., Forster K.K., Fischer M., et al. Efficacy and safety of intramuscular glucosamine sulfate in osteoarthritis of the knee. A randomised, placebo-controlled, double- blind study. Arzneimittelforschung. 44:(1):1994;75-80
58. Vajaradul Y. Double-blind clinical evaluation of intra-articular glucosamine in outpatients with gonarthrosis. Clin Ther. 3:(5):1981;336-343
59. Thie N.M., Prasad N.G., Major P.W. Evaluation of glucosamine sulfate compared to ibuprofen for the treatment of temporomandibular joint osteoarthritis: a randomized double blind controlled 3 month clinical trial. J Rheumatol. 28:(6):2001;1347-1355
60. Adams M.E. Hype about glucosamine. Lancet. 354:(9176):1999;353-354
61. Callaghan J.J., Buckwalter J.A., Schenck R.C. Jr. Argument against use of food additives for osteoarthritis of the hip. Clin Orthop. 381:2000;88-90
62. da Camara C.C., Dowless G.V. Glucosamine sulfate for osteoarthritis. Ann Pharmacother. 32:(5):1998;580-587
63. Towheed T.E., Anastassiades T.P. Glucosamine and chondroitin for treating symptoms of osteoarthritis: evidence is widely touted but incomplete. JAMA. 283:(11):2000;1483-1484
64. Towheed T.E., Anastassiades T.P., Shea B., et al. Glucosamine therapy for treating osteoarthritis. Cochrane Database Syst Rev. CD002946:2001
65. McAlindon T.E., LaValley M.P., Gulin J.P., et al. Glucosamine and chondroitin for treatment of osteoarthritis: a systematic quality assessment and meta-analysis. JAMA. 283:(11):2000;1469-1475
66. Hardingham T. Chondroitin sulfate and joint disease. Osteoarthritis Cartilage. 6:(Suppl A):1998;3-5
67. Bassleer C.T., Combal J.P., Bougaret S., et al. Effects of chondroitin sulfate and interleukin-1 beta on human articular chondrocytes cultivated in clusters. Osteoarthritis Cartilage. 6:(3):1998;196-204
68. Bartolucci C., Cellai L., Corradini C., et al. Chondroprotective action of chondroitin sulfate. Competitive action of chondroitin sulfate on the digestion of hyaluronan by bovine testicular hyaluronidase. Int J Tissue React. 13:(6):1991;311-317
69. Bassleer C., Henrotin Y., Franchimont P. In-vitro evaluation of drugs proposed as chondroprotective agents. Int J Tissue React. 14:(5):1992;231-241
70. Bali J.P., Cousse H., Neuzil E. Biochemical basis of the pharmacologic action of chondroitin sulfates on the osteoarticular system. Semin Arthritis Rheum. 31:(1):2001;58-68
71. Bourgeois P., Chales G., Dehais J., et al. Efficacy and tolerability of chondroitin sulfate 1200 mg/day vs chondroitin sulfate 3 × 400 mg/day vs placebo. Osteoarthritis Cartilage. 6:(Suppl A):1998;25-30
72. Bucsi L., Poor G. Efficacy and tolerability of oral chondroitin sulfate as a symptomatic slow-acting drug for osteoarthritis (SYSADOA) in the treatment of knee osteoarthritis. Osteoarthritis Cartilage. 6:(Suppl A):1998;31-36
73. Fioravanti A., Franci A., Anselmi F., et al. Clinical efficacy and tolerance of galactosoaminoglucuronoglycan sulfate in the treatment of osteoarthritis. Drugs Exp Clin Res. 17:(1):1991;41-44
74. Kerzberg E.M., Roldan E.J., Castelli G., et al. Combination of glycosaminoglycans and acetylsalicylic acid in knee osteoarthrosis. Scand J Rheumatol. 16:(5):1987;377-380
75. Mazieres B., Combe B., Phan Van A., et al. Chondroitin sulfate in osteoarthritis of the knee: a prospective, double blind, placebo controlled multicenter clinical study. J Rheumatol. 28:(1):2001;173-181
76. Mazieres B., Loyau G., Menkes C.J., et al. [Chondroitin sulfate in the treatment of gonarthrosis and coxarthrosis. 5-months result of a multicenter double-blind controlled prospective study using placebo]. Rev Rhum Mal Osteoartic. 59:(7-8):1992;466-472
77. Morreale P., Manopulo R., Galati M., et al. Comparison of the antiinflammatory efficacy of chondroitin sulfate and diclofenac sodium in patients with knee osteoarthritis. J Rheumatol. 23:(8):1996;1385-1391
78. Nguyen P., Mohamed S.E., Gardiner D., et al. A randomized double-blind clinical trial of the effect of chondroitin sulfate and glucosamine hydrochloride on temporomandibular joint disorders: a pilot study. Cranio. 19:(2):2001;130-139
79. Oliviero U., et al. Effects of the treatment with matrix on elderly people with chronic articular degeneration. Drugs Exp Clin Res. 17:(1):1991;45-51
80. Rovetta G. Galactosaminoglycuronoglycan sulfate (matrix) in therapy of tibiofibular osteoarthritis of the knee. Drugs Exp Clin Res. 17:(1):1991;53-57
81. Uebelhart D., Thonar E.J., Delmas P.D., et al. Effects of oral chondroitin sulfate on the progression of knee osteoarthritis: a pilot study. Osteoarthritis Cartilage. 6:(Suppl A):1998;39-46
82. Verbruggen G., Goemaere S., Veys E.M. Chondroitin sulfate: S/DMOAD (structure/disease modifying anti-osteoarthritis drug) in the treatment of finger joint OA. Osteoarthritis Cartilage. 6:(Suppl A):1998;37-38
83. Leeb B.F., Schweitzer H., Montag K., et al. A metaanalysis of chondroitin sulfate in the treatment of osteoarthritis. J Rheumatol. 27:(1):2000;205-211
84. Malaise M., Marcolongo R., Uebelhart D., et al. Efficacy and tolerability of 800 mg oral chondroitin 4 & 6 sulfate in the treatment of knee osteoarthritis: a randomised, double-blind, multi-center study vs. placebo. Mautone G., Tajana E., Rovanti S.,, et al. New approaches in OA, chondroitin sulfate (CS 4 and 6) not just a symptomatic treatment. 1999;15-20 Eular Publishers, Zurich (Switzerland)
85. Agrati A.M., Frigerio S., Palmieri G., et al. [The possible effects of galactosaminoglucuronoglycan sulfate on blood coagulation processes]. Studio delle eventualli influenze del galatto samingglucuronoglicano sulfato sui processi emo coagulativi (Italian) Minerva Med. 83:(9):1992;529-531
86. Brecher A.S., Adamu M.T. Coagulation protein function: enhancement of the anticoagulant effect of acetaldehyde by sulfated glycosaminoglycans. Dig Dis Sci. 46:(9):2001;2033-2042
87. Haas S., Stemberger A.W., Fritsche H.M., et al. Study of a dose-dependent effect of the glycosaminoglycan polysulfate on various parameters of blood coagulation. Semin Thromb Hemost. 17:(Suppl 2):1991;214-218
88. Boneu B., Buchanan M.R., Cade J.F., et al. Effects of heparin, its low molecular weight fractions and other glycosaminoglycans on thrombus growth in vivo. Thromb Res. 40:(1):1985;81-89
89. Kanaide H., Uranishi T., Nakashima Y., et al. The anticoagulant effect of chondroitin sulphates isolated from normal and atherosclerotic regions of human aortas. Br J Exp Pathol. 63:(1):1982;82-87
90. Van Ryn McKenna J., Gray E., Weber E., et al. Effects of sulfated polysaccharides on inhibition of thrombus formation initiated by different stimuli. Thromb Haemost. 61:(1):1989;7-9
91. Lippiello L., Woodward J., Karpman R., et al. Beneficial effect of cartilage structure modifying agents tested in chondrocyte cultures and a rabbit instability model of osteoarthrosis. Arthritis Rheum. 42:(9 (Suppl)):1999;2
92. Lippiello L., Woodward J., Karpman R., et al. In vivo chondroprotection and metabolic synergy of glucosamine and chondroitin sulfate. Clin Orthop. (381):2000;229-240
93. Das A. Jr., Hammad T.A. Efficacy of a combination of FCHG49 glucosamine hydrochloride, TRH122 low molecular weight sodium chondroitin sulfate and manganese ascorbate in the management of knee osteoarthritis. Osteoarthritis Cartilage. 8:(5):2000;343-350
94. Debi R., Robinson D., Agar G., et al. [GAG for osteoarthritis of the knee - a prospective study]. Harefuah 2000;138(6):451-3, 518
95. Leffler C.T., Philippi A.F., Leffler S.G., et al. Glucosamine, chondroitin, and manganese ascorbate for degenerative joint disease of the knee or low back: a randomized, double-blind, placebo-controlled pilot study. Mil Med. 164:(2):1999;85-91
96. Hughes R., Carr A. A randomized, double-blind, placebo-controlled trial of glucosamine sulphate as an analgesic in osteoarthritis of the knee. Rheumatology (Oxford). 41:(3):2002;279-284
97. de Mattei M., Pellati A., Pasello M., et al. High doses of glucosamine-HCl have detrimental effects on bovine articular cartilage explants cultured in vitro. Osteoarthritis Cartilage. 10:(10):2002;816
98. AbdelFattah W., Hammad T.A. Chondroitin sulfate and glucosamine: a review of their safety profile. JAMA. 3:(4):2001;16-23
99. Danao-Camara T. Potential side effects of treatment with glucosamine and chondroitin. Arthritis Rheum. 43:(12):2000;2853
100. Echard B.W., Talpur N.A., Funk K.A., et al. Effects of oral glucosamine and chondroitin sulfate alone and in combination on the metabolism of SHR and SD rats. Mol Cell Biochem. 225:(1-):2001;85-91
101. Taylor D.M., Ferguson C.E., Chree A. Absence of detectable infectivity in trachea of BSE-affected cattle. Vet Rec. 38:1996;160-161
102. Adebowale A., Cox D.S., Zhongming L., et al. analysis of glucosamine and chondroitin sulfate content in marketed products and the Caco-2 permeability of chondroitin sulfate raw materials. JAMA. 3:(1):2000;37-44
103. Baici A., Horler D., Moser B., et al. Analysis of glycosaminoglycans in human serum after oral administration of chondroitin sulfate. Rheumatol Int. 12:(3):1992;81-88
104. Reginster J.Y., Gillot V., Bruyere O., et al. Evidence of nutriceutical effectiveness in the treatment of osteoarthritis. Curr Rheumatol. 2:(6):2000;472-477
105. Conte A., Volpi N., Palmieri L., et al. Biochemical and pharmacokinetic aspects of oral treatment with chondroitin sulfate. Arzneimittelforschung. 45:(8):1995;918-925
106. Ronca F., Palmieri L., Panicucci P., et al. Anti-inflammatory activity of chondroitin sulfate. Osteoarthritis Cartilage. 6:(Suppl A):1998;14-21
107. Adebowale A., Du J., Liang Z., et al. The bioavailability and pharmacokinetics of glucosamine hydrochloride and low molecular weight chondroitin sulfate after single and multiple doses to beagle dogs. Biopharm Drug Dispos. 23:(6):2002;217-225
108. Setnikar I., Giacchetti C., Zanolo G. Pharmacokinetics of glucosamine in the dog and in man. Arzneimittelforschung. 36:(4):1986;729-735
109. Setnikar I., Rovati L.C. Absorption, distribution, metabolism and excretion of glucosamine sulfate. A review. Arzneimittelforschung. 51:(9):2001;699-725